The US Patent and Trademark Office (USPTO) has granted a patent to Vistagen’s non-opioid oral product candidate, AV-101 for ...

The Phase IIa results continue a surge of momentum in a treatment space that last week saw the approval of Vertex’s Journavx ...

The U.S. Food and Drug Administration has approved a novel prescription pain medication that targets sodium channels involved ...

Algiax Pharmaceuticals, a company committed to developing innovative treatments for chronic neuropathic pain, has released ...

Suzetrigine (Journavx) is the first non-opioid pain medication to be approved in the US in 20 years. It could help over 80 million Americans living with severe acute pain, while reducing the effects ...

Gabapentinoids are increasingly prescribed as an alternative to pain medicines for nursing home residents, but the reasoning behind the prescriptions — and beliefs about efficacy and deprescribing — ...

A new non-opioid painkiller, suzetrigine, has just been approved by the US drug regulator, the FDA. It is the first ...

As an orthopedic and sports medicine surgeon and chairman at Inova Sports Medicine, Dr. Robin West is no stranger to sports-related injuries. She understands that developing an effective game plan to ...

While cannabinoids offer a potential alternative for refractory chronic pain, optimal use requires personalized dosing and ...

Allosteric GABAA-receptor modulator AP-325 showed rapid onset as well as long-lasting pain reduction in patients with chronic neuropathic pain in Phase 2a study Data confirm previously reported ...

It is important to add pain management to leprosy treatment protocols. This can reduce the challenges that patients face. Read on.